Summary Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg 1t.d.s. for 23 days followed by oral acyclovir 800mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.
The introduction of acyclovir into clinical practice was a useful development in the management of herpesvirus infections (Selby et al., 1979) . The drug has been proved to be a highly effective treatment for herpes simplex (HSV) and varicella zoster virus (VZV) infections both in immune compromised and immune competent patients (Meyers et al., 1982; Balfour et al., 1983; Prober et al., 1982; reviewed by Fiddian & Grant, 1985; Prentice & Hann, 1985; Strauss, 1985; Gore & Selby, 1987) . The efficacy and lack of toxicity of acyclovir has led to its use to prevent reactivation of herpesvirus infections. It is effective in the prophylaxis of HSV reactivation both in the immune competent patient with, for instance, recurrent genital herpes simplex and in the immune compromised patient, after, for instance, allogeneic bone marrow transplantation (Saral et al., 1981; Gluckman et al., 1983; Wade, 1984; Fiddian & Grant, 1985; Prentice & Hann, 1985; Straus, 1985; Gore & Selby, 1987) . However, information about the prophylaxis of VZV infection is much less complete.
The concentrations of acyclovir that are required to inhibit VZV in vitro are much higher than those required to inhibit HSV. This observation, together with the limited absorption of acyclovir when given by the oral route (Brigden & Whiteman, 1985) , led to doubt about the effectiveness of acyclovir for the oral treatment or prophylaxis of VZV. However, it has been shown that oral acyclovir in high doses is effective in shortening the duration of VZV infections in immune competent patients (Peterslund, 1985; McKendrick et al., 1986) .
Reactivation of both HSV and VZV after bone marrow transplantation are a common source of morbidity. Up to 70% of patients who are seropositive for HSV infection develop reactivations and 40% of patients get herpes zoster or varicella (Saral et al., 1981; Locksley et al., 1985) . However, evidence that long-term oral acyclovir will prevent the development of VZV was inconclusive. We have therefore carried out a prospective randomised double blind trial of intravenous acyclovir given for 23 days followed by oral acyclovir for 6 months in patients following allogeneic bone marrow transplantation. (Freedman & White, 1976) .
Acyclovir or placebo was administered to adults at a dose of 5mg kg-1 in 100 ml of normal saline infused over 1 h, given 8-hourly starting on the day before transplantation and continuing for 23 days. At that point adults received 800mg tablets 6-hourly for 6 months. Children less than 12 years of age received 250 mg m-2 acyclovir intravenously followed by 400mg orally 6-hourly. Patients were prepared for transplantation by treatment with intravenous cyclophosphamide 1.8gm-2 daily for 2 days or with melphalan lOmgm-2 intravenously and both of these drug treatments were followed by 10-11.5 Gy total body irradiation in a single dose. Prophylaxis against graft versus host disease was given with oral cyclosporin A 8 mg kg-1 day 1. All patients were nursed in protective isolation cubicles.
Pre-transplant assessments included a careful history of previous HSV or VZV infection and of any recent contact with such infections. Pre-transplant sera were analysed for IgG antibodies against VZV, HSV and CMV. During the period of transplantation patients were routinely clinically examined twice weekly for evidence of virus infection and the viral serological tests were repeated weekly in addition to urine and buffy coat cultures for herpesviruses. Throat washings and mouth swabs for virus culture were taken weekly or when clinically indicated. After discharge both serological and viral culture tests were repeated at each clinic visit for one year post-transplant.
The criteria for a diagnosis of VZV were a typical clinical picture confirmed virus isolation when appropriate. HSV infection was diagnosed by viral culture. Cytomegalovirus (CMV) infection was diagnosed by viral culture or by early antigen detection in tissue culture.
When a patient developed HSV or VZV infection, the trial regimen was discontinued without breaking the code and commercially available acyclovir was substituted in a conventional dose for 7 days. At the end of this treatment the trial acyclovir or placebo was restarted. Two infections with herpes simplex virus was felt to indicate long-term use of open acyclovir and this was instigated. In the case of suspected acyclovir toxicity the trial drug was stopped.
Statistical analysis
The principal analyses were of the time to first HSV, VZV and CMV infections; the period of risk was considered to start on day 5. Infections occurring in the first 4 days after transplantation were excluded from the analysis because it seemed likely that these had started before the transplant.
Time-to-event curves were analysed for HSV infection, CMV infection, haematological recovery and the development of abnormal renal function. In these curves, the cumulative probability of the end-point is plotted against time from transplant and patients are censored at the point of followup or at death from other causes.
Differences between acyclovir and placebo arms were tested by log rank tests in each case. Because the intention was to treat each patient for 6 months, the analysis has been subdivided into periods of risk up to 6 months and beyond 6 months.
Results
Forty-two patients were randomised to receive intravenous followed by oral acyclovir and 40 patients to receive the matching placebos. Table I shows the patient characteristics. In general the groups were well balanced according to important prognostic variables. An excess of patients who were seropositive for VZV and CMV is seen in the acyclovir treatment arm of the trial.
All patients were followed for at least one year beyond the time of transplantation and follow-up was completed in May 1987. Prophylactic effect Time-to-event curves for virological evidence of HSV infection, clincial evidence of VZV infection and virological evidence of CMV infection are shown in Figures 1-3 . Logrank analysis of these curves is given in Table II. Herpes simplex virus (HSV) A highly statistically significant reduction in HSV infection during the period of administration of acyclovir is seen. When acyclovir was stopped at 6 months, reactivations quickly ensued in four patients but there was a statistically significant overall reduction in HSV infections for the whole period of observation to one year. Varicella zoster virus (VZV) There was complete and highly significant abolition of VZV infection during the period of administration of acyclovir. When acyclovir was discontinued at 6 months infections were seen quickly so that there was no overall reduction in VZV infection over the whole observation period of one year.
Cytomegalovirus There was no overall reduction in the occurrence of CMV infection during the administration of acyclovir at the doses used in this study. When the subgroups of CMV seropositive and seronegative patients were analysed separately no significant reduction in CMV infection rate was found in the acyclovir treated patients (Table III) . Months since transplant ---Control -6 Month ACV Figure 4 Cumulative probability of the serum creatinine increasing to abnormal levels (> 106 mm 1-1) in patients receiving acyclovir (solid line) or placebo (dotted line). which no virological diagnosis was forthcoming. Most of these were presumably due to cytotoxic drugs or other infections.
Discussion
The study shows the abolition of VZV infection during the administration of oral acyclovir. This is in keeping with a smaller study published by Lundgren et al. (1985) . The effectiveness of oral acyclovir for this purpose confirms that sufficient absorption occurs to achieve plasma levels capable of inhibiting the replication of the virus. Unfortunately, once the administration of acyclovir was stopped at 6 months, varicella zoster virus infections recurred and there was no overall reduction in infection rate for the year of observation. It is possible that more prolonged administration of acyclovir might have suppressed the virus until the patients' immune function had recovered sufficiently to prevent subsequent reactivations. A trial of one year's administration of oral acyclovir is now under 0 1 2 3 4 5 6 7 8 9 10 o1l l2 consideration. T his study also contirms that both intravenous and oral acyclovir can significantly reduce the Months since transplant rate of infections with HSV after allogeneic bone marrow ---Control -6 Month ACV transplantation. This has been previously shown by others (Wade et al., 1984; Gluckman et al., 1983; Saral et al., 1981 ; Acyclovir prophylaxis study Hann et al., 1983; Shepp et al., 1987) . Meyers et al. (1988) have observed a reduction in CMV infection in patients given larger doses of acyclovir (500 mg m -2) compared to a concurrent, non-randomised, control group. If acyclovir has an effect against cytomegalovirus it may only be with the administration of these large doses and multi-centre studies to evaluate this further are now planned.
We did not document any significant evidence of toxicity of acyclovir in this trial. It 
